Table 1 Targeted therapies studied or under investigation in cooperation with immune therapies
From: Oncogene withdrawal engages the immune system to induce sustained cancer regression
Target protein(s) | Tumor type | Targeted therapy | Immune therapy | Refs |
|---|---|---|---|---|
ALK | Non-Small Cell Lung Cancer | Crizotinib | Ipilimumab | [119] |
BCR-ABL | CML, GIST | Imatinib, Dasatinib | Interferon, Nivolumab | [125] |
BRAF | Melanoma | Vemurafenib, Dabrafenib | Ipilimumab | [117] |
BTK | Chronic Lymphocytic Leukemia | Ibrutinib | Lenalidomide | [122] |
CD20 | Follicular Lymphoma | Rituxamab | Pidilizumab | [126] |
CD30 | Hodgkin’s Lymphoma | Brentuximab | Ipilimumab | [118] |
EGFR | Non-Small Cell Lung Cancer | Erlotinib | Ipilimumab, anti-PDL1 (MPDL3280A) | |
HER2/neu | Breast Cancer | Trastuzumab | E75 peptide + GM-CSF | [127] |
MEK | Melanoma | Trametinib | Ipilimumab | |
mTOR | Renal Cell Cancer | Temsirolimus | Interferon-α | [124] |
PDGFR, RET, or KIT | Kidney Cancer | Sunitinib | Nivolumab | [123] |
Proteosome, NF-kB | Multiple Myeloma | Bortezomib | Lenalidomide | [121] |
VEGF | Melanoma | Aflibercept | IL-2 | [116] |